Metagenomi Therapeutics (MGX)See Remarks sold ~$771

~$771

Approx. value · 482 sh @ $1.60

115K

Holds after · shares reported

Traded

Mar 5, 2026

Filed

Mar 9, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 12, 2026Company filing · Form 8-K · Bylaws or charter, Reg FDChanged its bylaws, charter or fiscal year, and shared information with investors
2. Mar 5, 2026 · this disclosureInsiderOfficer sold ~$771 of MGX shares in the open market

What came next

1. Mar 5, 2026Company filing · Form 8-K · ResultsReported its results
2. Mar 5, 2026Insider · 2 peopleInsiders: 2 sales (~$5K)
3. May 11, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
4. Jun 5, 2026Insider · 3 peopleInsiders: 3 sales (~$9K)
5. Jun 9, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the “Board”) of Metagenomi Therapeutics, Inc. (the “Company”) of his resignation from his position as a member of the Board, effective as of June 9, 2026.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Metagenomi Therapeutics

For Metagenomi Therapeutics, OQRO holds 5 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MGX page.

Other recent filings by Matthew Wein, See Remarks

• SEC Form 4 at Metagenomi Therapeutics (MGX)Sep 10, 2026
• SEC Form 4 at Metagenomi Therapeutics (MGX)Jun 10, 2026
• SEC Form 4 at Metagenomi Therapeutics (MGX)Dec 8, 2025
• SEC Form 4 at Metagenomi Therapeutics (MGX)Dec 1, 2025
• SEC Form 4 at Metagenomi Therapeutics (MGX)Jun 9, 2025

The full history of Matthew Wein, See Remarks is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Metagenomi Therapeutics

• SEC Form 4Sep 11, 2026
• SEC Form 4Sep 11, 2026
• SEC Form 4Sep 10, 2026
• SEC Form 4Sep 10, 2026
• SEC Form 4Sep 10, 2026
• SEC Form 4Jun 10, 2026

Everything OQRO holds on this company is on its MGX page.